A compound of the Formula I
1
a prodrug thereof, or the pharmaceutically acceptable salt of the compound or prodrug; wherein X, Y, a, b, c, d, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
are as defined above and are useful to treat inflammation and other immune disorders. The present invention also relates to pharmaceutical compositions that include compounds of Formula I and a pharmaceutically acceptable carrier. Moreover, the present invention relates to methods of using the above-described compounds and compositions to treat and prevent diseases and conditions.
The Synthesis of Phosphaisocoumarins by Cu(I)-Catalyzed Intramolecular Cyclization of <i>o</i>-Ethynylphenylphosphonic Acid Monoesters
作者:Ai-Yun Peng、Yi-Xiang Ding
DOI:10.1021/ja038627f
日期:2003.12.1
Cu(I)-catalyzed intramolecular cyclization of o-ethynylphenylphosphonic acid monoethyl esters was examined, and a new class of six-membered phosphorus heterocycles was formed with high regioselectivity and good yields. The present reaction is the first example of intramolecular addition of P-OH to alkynes, which provides a convenient way to synthesize novel phosphorus heterocycles having potential
1,3-carbanionische umlagerungen: Reaktionen von phosphorsäure-o-haloarylestern mit metallen zu arylphosphonsäurederivaten
作者:J. Heinicke、I. Böhle、A. Tzschach
DOI:10.1016/s0022-328x(00)99340-9
日期:1986.12
o-Bromoaryl esters of phosphoricacid react with magnesium to give arene phosphonic acidderivatives via intermediate Grignard compounds. Similar metallation rearrangement processes may be achieved in the case of o-chloroaryl esters if sodium is applied as metal. 2,4-Dibromoaryl esters are attacked by magnesium regiospecifically in o-position.
Due to the importance of pancreatic cholesterol esterase (CEase) as a potential target in atherosclerosis and for the development of hypocholesterolemic agents, there are increasing interests in designing and synthesizing CEase inhibitors. In the present study, we prepared forty-five isocoumarin phosphorus analogues (i.e., phosphaisocoumarins) and investigated the inhibition of these compounds on the CEase. The results showed that some phosphaisocoumarins could act as potent inhibitors of CEase. The most potent inhibitors, compounds 9d, 10a and 12e give IC(50) values of 4.8 mu M, 2.3 mu M and 1.9 mu M, respectively. The inhibition mechanism and kinetic characterization studies indicate that they are reversible competitive inhibitors. (C) 2010 Published by Elsevier Masson SAS.